Visceral leishmaniasis (VL) in Brazil is caused by the intracellular pathogen *Leishmania chagasi* and is almost always lethal if not treated (4). A persisting question has been why only a small proportion of infected individuals develop disease (4). Most infections will remain cryptic unless immunological suppression occurs (2). Young age, malnutrition, and human immunodeficiency virus infection are risk factors for VL (2, 4), but other host susceptibility factors remain unknown. Mannan-binding lectin (MBL), a multichain serum lectin and a component of innate immunity (10), is a candidate molecule for modifying disease progression because of its possible enhancement of innate immunity (10), is a candidate molecule for modifying disease progression because of its possible enhancement of innate immunity (10). Three independent mutations at exon 1 result in amino acid substitutions in a collagenous region of the lectin seen in a population (13): whereas low concentrations or exon 1 mutations have been associated with recurrent or severe infections in children and adults caused by extracellular pathogens (16, 29) and *Plasmodium falciparum* (19), high concentrations may enhance targeting of intracellular organisms to host phagocytes, the milieu preferred by these pathogens. We addressed this hypothesis by evaluating levels of MBL in VL in a case-control study of a population from Teresina, Piauí State, Brazil, where urban epidemics have occurred since 1980 (8) and where there is no transmission of Chagas’ disease or cutaneous leishmaniasis. Individuals presenting with active VL (aVL) or a documented history of this disease and cured for at least 5 months (median, 316 days) (cVL) before sample collection were compared with healthy, Montenegro (leshinian) skin test (MST)-positive or MST-negative individuals recruited from the same background and with no history of VL. Informed consent and institutional approval were obtained. Individuals were between 1 and 80 years of age (mean, 22.5 ± 16.2 years) and represent an admixture of African, Caucasian, and native American populations estimated, respectively, at 31, 21, and 48% (3). Diagnosis of VL was confirmed by isolation of parasites from bone marrow, and MST-positive individuals were considered to be infected. Serum MBL concentrations were measured in a double-antibody immune assay (30).

We took every step to ensure that, with the exception of aVL, the levels of MBL in serum measured were baseline. Levels vary during infection, reflecting acute phase reactions (12) or consumption by pathogens (1). The following data suggest that in cured and MST-positive individuals the load of *L. chagasi* is insufficient to trigger acute phase responses: (i) DNA-based detection of *L. chagasi* (9, 26) was positive in 76% of individuals with aVL versus 8% of patients with cVL or asymptomatic infection, and (ii) xenodiagnosis was negative in all MST-positive or cured individuals and positive in 40% of patients with aVL (9).

We thus examined the association between clinical outcome of infection with *L. chagasi* and MBL as a quantitative trait. MBL phenotypes (baseline levels) are associated with the outcome of infection with *L. chagasi*: levels were significantly lower in individuals infected with *L. chagasi* (aVL) than in healthy, MST-positive individuals (negative controls). We thus report that higher levels of MBL are associated with the outcomes of infection with *L. chagasi*.
higher \( (P < 0.003) \) in individuals with a history of VL than in infected, asymptomatic individuals (Fig. 1a) (median MBL concentrations in cVL patients \( n = 34 \), 2,888 \( \mu \)g/liter; in MST-positive, asymptomatic individuals \( n = 55 \), 1,113 \( \mu \)g/liter; and in exposed, MST-negative, healthy individuals \( n = 20 \), 944 \( \mu \)g/liter). There was no association between levels of MBL and the sex or age of individuals. MBL phenotypes were directly correlated with the probability of developing VL (Fig. 1b), indicating a threshold effect of levels on the clinical outcome upon infection with \( L. \) chagasi.

We next examined the association between exon 1 genotypes and outcome upon infection with \( L. \) chagasi. DNA was extracted with a Puregene kit (Gentra Systems), and PCR-restriction fragment length polymorphism typing of exon 1 was done as described previously (20). We determined that 50% of individuals had at least one exon 1 mutation (allele frequencies were 0.71, 0.16, 0.09, and 0.04 for A, B, C, and D, respectively; genotypes were AA, 50%; AO, 42%; OO, 8%; \( n = 108 \)), the second highest frequency described to date (17, 21). Mutations were more frequent among MST-positive, healthy individuals and MST-negative individuals than among individuals who developed VL. Conversely, wild-type genotypes were more frequent among VL patients (Table 1). However, neither stepwise nor multiple regression analysis revealed a significant association between exon 1 genotypes and outcome upon exposure to infection with \( L. \) chagasi. Exon 1 genotypes did not have a

FIG. 1. MBL levels correlate to clinical outcome upon exposure to \( L. \) chagasi. (a) Box-whisker plots of serum MBL concentrations in different clinical-epidemiological categories: levels of MBL in serum are significantly (Kruskal-Wallis: \( H = 14.2, 3 \) df, \( P < 0.003 \)) associated with clinical outcome upon infection with \( L. \) chagasi. (b) Logistic regression analysis of the probability of developing VL according to serum MBL concentrations: levels of MBL are directly and significantly correlated (likelihood ratio test = 11.55; 1 df, \( P < 0.001 \)) with the probability of developing VL.
major effect on outcome. MBL phenotypes depend, however, on the set of alleles not only at exon 1 but also at the promoter. The LX promoter haplotype has the same effect on levels of MBL as do exon 1 structural mutants (20). We plan to examine whether promoter haplotypes associated with lower levels of protein transcription are more frequent in asymptomatic individuals.

We next investigated the physiological basis for the associations observed in this population. Innate immunity can determine the outcome of adaptive immune responses to pathogens (22). MBL may regulate the availability of pathogen-derived polymannose structures for CD1b molecules (24) and of oligosaccharide for induction of T cells (32) and may affect the function of macrophages (6). We therefore examined whether MBL modulates the pattern of cytokines secreted by monocytes infected with MBL-opsonized *L. chagasi* promastigotes.

First passage, stationary-growth-phase promastigotes were grown as described previously (14), washed three times, and resuspended in Hanks balanced salt solution containing 10 mM CaCl$_2$ (Gibco) at $2 \times 10^6$ parasites/ml. Aliquots were mixed with an equal volume of recombinant human MBL (30) at the final concentrations indicated in Fig. 2. Parasites were incubated on ice for 1 h and then washed three times in Hanks balanced salt solution-Ca$^{2+}$-buffer, resuspended in the same volume of the original aliquot, and used to infect peripheral blood mononuclear cells (PBMCs) or the myelomonocytic cell line THP-1. PBMCs ($3.5 \times 10^6$/well in a 24-well plate) and THP-1 cells ($1 \times 10^6$/well in a 24-well plate) were washed and cultured in complete RPMI medium containing 10% fetal calf serum without antibiotics. Gamma interferon was added at a final concentration of 100 ng/ml. After 18 h, cultures were infected with opsonized or nonopsonized promastigotes at a parasite-to-cell ratio of 1:2 for THP-1 cells and 1:3.5 for PBMCs. After 24 h, cytokines were measured in supernatants by capture assay (PharMingen). Levels of LPS in supernatants were below the detection limit of the limulus amebocyte assay (BioWhittaker).

Secretion of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) was enhanced in a dose-dependent manner (respectively, $P < 0.001$ and $P < 0.04$) in both THP-1 cells and normal human PBMCs infected with promastigotes opsonized with MBL (Fig. 2a and b). We examined and did not see differences in the levels of IL-1α, IL-10, or IL-12. IL-6 and

---

**TABLE 1. MBL genotypes associated with clinical outcome of exposure to *L. chagasi***

<table>
<thead>
<tr>
<th>Genotype$^a$</th>
<th>No. (%) of unrelated individuals with indicated genotype by clinical status:</th>
<th>MST$^b$+</th>
<th>MST$^b$–</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>28 (60)</td>
<td>20 (46)</td>
<td>6 (33)</td>
<td>54</td>
</tr>
<tr>
<td>AO</td>
<td>17 (36)</td>
<td>18 (42)</td>
<td>10 (56)</td>
<td>45</td>
</tr>
<tr>
<td>OO</td>
<td>2 (4)</td>
<td>5 (12)</td>
<td>2 (11)</td>
<td>9</td>
</tr>
<tr>
<td>AO/OO</td>
<td>19 (40)</td>
<td>23 (54)</td>
<td>12 (67)</td>
<td>54</td>
</tr>
<tr>
<td>Total</td>
<td>47</td>
<td>43</td>
<td>18</td>
<td>108</td>
</tr>
</tbody>
</table>

$^a$Nomenclature for the alleles (21): A for the functional, wild-type allele; B, C, and D for the individual mutant alleles, which are collectively called O since they all result in lower levels of protein.

$^b$MST$^+$, MST positive; MST$^–$, MST negative.
TNF-α are inflammatory cytokines, and higher levels of MBL could enhance microbialidal mechanisms in the macrophage by increasing production of these cytokines. IL-6 and TNF-α are, however, clearly elevated in VL (5, 31), and in spite of their microbiocidal-enhancing capacity, they do not promote control of the parasite. Increased IL-6 production is related to polyclonal B-cell activation and hyperangmaglobulinemia, hallmark of VL (31). This cytokine also inhibits the leishmanicidal capacities of macrophages infected with *Leishmania mexicana* (15). Mice deficient in IL-6 can control infection with *Leishmania major* (23, 27). Although TNF-α and IL-6 both seem to be involved by modulating production of these inflammatory cytokines, we show that, in vitro, MBL affects the function of *L. chagasi*-infected macrophages.

We thank Peter Garred for sharing data before publication and John David, Phillip Stahl, Antonio Campos Neto, Richard C. Lewontin, and Siamon Gordon for helpful suggestions.

We acknowledge the financial support of the Conselho Nacional de Desenvolvimento Científico e Tecnológico—CNPq (grant 20.1145/95-2 to E. M. Carvalho, H. Rocha, R. Teixeira, and W. D. Johnson, Jr.).

REFERENCES


